focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,172.00
Bid: 12,168.00
Ask: 12,170.00
Change: -74.00 (-0.60%)
Spread: 2.00 (0.016%)
Open: 12,240.00
High: 12,306.00
Low: 12,132.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks start second half in green amid PMIs

Mon, 03rd Jul 2023 09:07

(Alliance News) - European markets rose at Monday's open, kicking off the start of the second half on a positive note, boosted by strong trading in Asia and New York,

The FTSE 100 index opened up 18.52 points, 0.3%, at 7,550.05. The FTSE 250 was up 72.89 points, 0.4%, at 18,489.65, and the AIM All-Share was up 0.65 point, 0.1%, at 754.16.

The Cboe UK 100 was up 0.2% at 753.09, the Cboe UK 250 was up 0.3% at 16,141.46, and the Cboe Small Companies was up 0.1% at 13,727.97.

"The FTSE 100 opened marginally higher, helped by the tailwinds of a strong session in Asia and on Wall Street on Friday. But it's still struggling to find significant momentum, dragged down by concerns about growth in China and the wider global economy," commented Hargreaves Lansdown's Susannah Streeter.

In European equities, the CAC 40 in Paris was up 0.2%, while the DAX 40 in Frankfurt was up 0.3%.

Shares in Tesla were up 5.2% in Frankfurt after the US automaker said deliveries in the second quarter beat market estimates.

The electric car maker delivered 466,140 vehicles, an 83% increase year-on-year and above estimates of 450,000.

"The electric vehicle giant has benefitted from US federal credits which are designed to encourage consumers to shift away from diesel and petrol cars," interactive investor's Victoria Scholar said. "Its strategy to cut prices this year has also paid off amid the macroeconomic headwinds but could weigh on profit margins ahead."

Tesla's production is still a long way below that of major car makers such as Toyota, which produced nearly 950,000 vehicles in May alone this year.

In Asia on Monday, markets took their cue from the strong performance on Wall Street, despite some mixed economic data for the region.

The Nikkei 225 index in Tokyo closed up 1.7%, with Toyota up 0.7%.

In China, the Shanghai Composite closed up 1.3%, while the Hang Seng index in Hong Kong was up 2.3%. The S&P/ASX 200 in Sydney closed up 0.6%.

Early economic data pointed towards a slowdown in Asian manufacturing.

The Caixin purchasing managers' index for China's manufacturing indicated marginal growth in June, albeit at a slower pace than in May. Meanwhile, the au Jibun Bank PMI for Japan showed its manufacturing sector slipped back into a slight contraction. Respondents in Japan noted especially weak demand from mainland China, with exports orders continuing to fall.

In the US on Friday, Wall Street ended higher, with the Dow Jones Industrial Average up 0.8%, the S&P 500 up 1.2% and the Nasdaq Composite up 1.5%. Sentiment was lifted by a cooler-than-expected US inflation print, which boosted hopes that the Federal Reserve's rate-rising spree might be close to an end.

Still, the dollar was firm against other major currencies in early exchanges in Europe on Monday.

Sterling was quoted at USD1.2670, lower than USD1.2706 at the London equities close on Friday. The euro traded at USD1.0880, lower from USD1.0916. Against the yen, the dollar was quoted at JPY144.75, up versus JPY144.58.

In London, supermarket chain Tesco rose 0.9% as it named Gerry Murphy as its new chair from September 1.

Murphy is currently chair of luxury fashion firm Burberry and food supplier Tate & Lyle, and will step down from his role at the latter to "ensure he has sufficient capacity" for his new role at Tesco.

Murphy was also previously CEO at Kingfisher, and has held non-executive directorships at companies including British American Tobacco and Reckitt Benckiser.

Shares in Tate & Lyle fell 0.5%, while Buberry was trading flat.

Anglo American rose 2.3%, as it announced late on Friday that its diamond business, de Beers, reached an eleventh-hour deal with the Botswanan government. This followed months of tense negotiations that saw the continent's top producer threatening to cut ties with the storied diamond company.

The Botswana government and Anglo-American, have reached an "agreement in principle", the two sides said in a statement issued late Friday. The agreement provides for a new 10-year agreement to sell the rough diamonds produced by Debswana – a joint venture equally owned by the government and De Beers – and a 25-year extension of its mining licenses.

AstraZeneca fell 5.9% in early trade - the worst large-cap performer - as it announced high-level results from the Tropian-Lung01 phase III trial.

The trial looked at datopotamab deruxtecan, or Dato-DXd, in advanced non-small cell lung cancer. In patients will locally advanced or metastatic NSCLC treated with at last one prior therapy, the treatment showed a "statistically significant" improvement for the dual primary endpoint of progression-free survival compared to docetaxel, the current standard of care chemotherapy.

However, for the dual primary endpoint of overalll survival, the data "were not mature".

"An early trend was observed in favour of datopotamab deruxtecan versus docetaxel that did not meet the prespecified threshold for statistical significance at this interim analysis," AstraZeneca said.

The trial will continue as planned in order to assess OS with greater security.

On AIM, Yourgene Health more than doubled in value, with its shares reaching 0.47 pence from 0.20p on Friday.

The molecular diagnostic group has agreed a cash takeover offer with Novacyt UK, a wholly-owned subsidiary of fellow AIM listing Novacyt. The offer of 0.522p a share values the company at GBP16.7 million.

Novacyt is a biotechnology group focused on clinical diagnostics. Its shares were up 16%.

"The acquisition combines highly complementary technologies and services, with the enlarged group able to leverage mutual research and development capabilities for ongoing product development and portfolio enhancement to improve the customer offering," the companies said.

Gold was quoted at USD1,916.08 an ounce early Monday, higher than USD1,915.48 on Friday. Brent oil was trading at USD75.28 a barrel, little changed from USD75.58

There are more manufacturing PMI readings to come, including the UK at 0930 BST and the US at 1445 BST.

Financial markets in New York close at 1300 local time on Monday for Independence Day. They stay closed on Tuesday for the US public holiday.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 17:22

UK's FTSE 100 pressured by stronger pound; miners climb

FTSE 100 flat, FTSE 250 up 0.2%

*

Read more
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.